Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation

  • Lingyan Wang Zhongshan Hospital Institute of Clinical Science, Fudan University ,Shanghai 200032, China; Shanghai Institute of Clinical Bioinformatics,Shanghai 200032,China
  • Li-Hao Huang Department of Pathology and Immunology,Washington University in St.Louis, School of Medicine
  • Qi Shen Zhongshan Hospital Institute of Clinical Science, Fudan University ,Shanghai 200032, China; Shanghai Institute of Clinical Bioinformatics,Shanghai 200032,China
  • Fangming Liu Zhongshan Hospital Institute of Clinical Science, Fudan University ,Shanghai 200032, China; Shanghai Institute of Clinical Bioinformatics,Shanghai 200032,China
  • Bijun Zhu Zhongshan Hospital Institute of Clinical Science, Fudan University ,Shanghai 200032, China; Shanghai Institute of Clinical Bioinformatics,Shanghai 200032,China
  • Duojiao Wu Zhongshan Hospital Institute of Clinical Science, Fudan University ,Shanghai 200032, China; Shanghai Institute of Clinical Bioinformatics,Shanghai 200032,China
Received: 12 September 2017
Accepted: 2 March 2018
Published: 15 March 2018
DOI: 10.26781/2052-8426-2018-04

Abstract

BACKGROUND:


Phosphoinositide 3-kinase (PI3K) plays an important role in cellular proliferation  and tumor progression. The objective of this study is to evaluate the potential mechanism and therapeutic effects of new PI3K inhibitor SHBM1009 on various cancer cells of digestive system on proliferation.


METHODS:


Six human hepatocellular carcinoma cell lines including 97H, 97L, A3, F11, MHCC-1, SMMC7721, one gastric cell line SGC-7901 and three primary testicular cancer TYST,TYST1,TYST2 cells were treated by 100ng/ml epidermal growth factor with or without 1uM NVP-BEZ-235 and SHBM1009  in Cell-IQ system in 24-well plates for 48h and up to 72h. The cell bio-behaviors, especially for cell proliferation of total cell number were measured by a real-time cell monitoring system, Cell-IQ continuous cell culturing platform. Images were captured at 30 min intervals. Cell-IQ system uses machine vision technology for monitoring and recording time-lapse data, and the cell functions and morphological parameters were quantified and analyzed.


RESULTS:


SHBM1009 could prevent EGF-induced cancer cells proliferation. Different patterns of inhibitory effects of SHBM1009 and NVP-BEZ-235, a dual PI3K/mechanistic target of rapamycin inhibitor, on EGF-induced cancer cells proliferation were observed.


CONCLUSIONS:


PI3K plays a critical role in the development of cancer progress, including proliferation, differentiation and anti-apoptosis. SHBM1009, a new PI3K inhibitor, could be new therapeutic alternatives for cancer treatment.

Keywords

PI3K, cancer, cell proliferation, real-time cell monitoring
Published
2018-03-15
How to Cite
WANG, Lingyan et al. Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation. Molecular and Cellular Therapies, [S.l.], v. 6, n. 1, mar. 2018. ISSN 2052-8426. Available at: <http://molcelltherapies.com/article/view/114>. Date accessed: 23 june 2018. doi: https://doi.org/10.26781/2052-8426-2018-04.
Article Type
Original Research